Introduction
Wegener's granulomatosis (WG) and microscopic polyarteritis (MPA) are systemic vasculitides of uncertain aetiology characterized by chronic polymorphonuclear leucocyte infiltration within and around vessel walls at various sites throughout the body. Recent demonstration of circulating autoantibodies to neutrophil cytoplasm antigens (ANCA) has implicated autoimmune mechanisms in the pathogenesis of systemic vasculitis. 1 The role of ANCA in pathogenesis remains uncertain: deposition of immunoglobulin is not common in affected tissues, and this has led to the speculation that cellular mechanisms may be at least as important as humoral abnormalities in the development of tissue injury in these conditions.2 The role of T-lymphocytes in these conditions has not been extensively studied. One would argue that a breakdown in tolerance at the T-lymphocyte level has occurred as T-lymphocyte help is required for most antibody production, and ANCA have the characteristics of T-lymphocyte-dependent antibodies (IgG isotype and high affinity). Indirect evidence of a role for T-lymphocytes is provided by their presence in involved tissues,3'4 although a definitive role for T-lymphocytes in pathogenesis is hard to prove.
Activation of T-lymphocytes not only leads to the expression of interleukin 2 receptor (IL2R) molecules on the cell surface' but also releases soluble IL2R (sIL2R) molecules into the circulation.6 Previous studies have confirmed a strong association of serum sIL2R levels with the activation of T-lymphocytes in vitro, and have indicated the sIL2R production is directly proportional to cellular IL2R expression.6'7 Markedly elevated levels of sIL2R have been reported in diseases involving T-lymphocytes such as haematological malignancy,8 systemic lupus erythematosus,9 and IgA nephropathy.'0 In the present study, we attempted to explore the role of T-lymphocytes in systemic vasculitis by measuring the sIL2R and to compare the levels with the titres of ANCA which satisfactorily reflect the disease activity.
Materials and methods

Patients
Seven patients with systemic vasculitis were studied. Each patient was studied for at least 6 months (mean 12.7 months). (median 74%, range 33 -118%). The serum ANCA levels fell with clinical improvement following immunosuppressive therapy with or without plasma exchange. During clinical remission, the serum ANCA levels were often within the range of normal control. Nonetheless, the serum ANCA progressively rose before or immediately following clinical exacerbation. The characteristic profile of ANCA in these patients is illustrated in Figure 1 . Similarly, the serum sIL2R levels were elevated in all vasculitic patients at first clinical presentation (median 1,090 U/ml, range 760-1,588 U/ml). Nevertheless, the serum sIL2R levels frequently remained elevated despite apparent clinical improvement following immunosuppressive therapy with or without plasma exchange. During clinical remission, the serum sIL2R levels not infrequently remained elevated or at the upper limit of the normal range. An obvious rise of serum sIL2R level detected before or immediately following clinical exacerbation was not frequently sIL2R lU/ml) 8 12 weeks observed. Examples of these phenomena are illustrated in Figure 1 . elevated, whereas interleukin 1-P, gamma-interferon, and tumour necrosis factor-alpha levels remained within normal limits. In view of the high IL2 levels, it was tempting for these authors to speculate that vasculitis might be a T-lymphocytedependent immunopathological reaction, although the origin of these cytokines was not studied.
In conclusion, these preliminary data reveal that serum sIL2R levels are often elevated in systemic vasculitis during clinical exacerbation suggesting T-lymphocytes may be activated in the acute phase of the disease. Nonetheless, the finding of elevated serum sIL2R levels in most patients during clinical remission indicates that it is not a satisfactory measure of the disease activity and tends to argue against the role of T-lymphocytes as a major effector mediating inflammatory injuries in systemic vasculitis.
